MedTrace Logo

Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study

NCT00477373 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2008-12-19

No results posted yet for this study

Summary

To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode according to DSM IV (APA 1994) over a 12 weeks period of treatment.

To evaluate the clinical safety of Di-valproate.

Conditions

Interventions

DRUG

depakine chrono

Depakine Chrono 500 mg

Sponsors & Collaborators

Principal Investigators

  • Hisham - MAHMOUD, MD · Sanofi-aventis administrative office Gulf

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2007-12-31

Countries

  • Bahrain
  • Kuwait
  • Oman
  • Qatar

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477373 on ClinicalTrials.gov